SCHEMBL13701809

SCHEMBL13701809

Cn1cc(C(=O)NC(C)(C)C)ccc1=O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CREBBP Q92793 1/20 0.50
KMT2A Q03164 4/20 0.46
HTT P42858 4/20 0.46
MEN1 O00255 3/20 0.46
MAPT P10636 2/20 0.46
POLB P06746 1/20 0.46
KDM4E B2RXH2 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
ALDH1A1 P00352 5/20 0.44
LMNA P02545 3/20 0.44
HPGD P15428 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 1/20 0.41
MITF O75030 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
IMPDH2 P12268 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13702366 0.80 BRD4 (0.54) CREBBPKMT2AHTTMEN1MAPT
SCHEMBL13701807 0.80 BRD4 (0.45) HTTMAPTPOLBALDH1A1LMNA
SCHEMBL13701808 0.80 BRD4 (0.45) HTTMAPTPOLBALDH1A1LMNA
SCHEMBL13701804 0.79 BRD4 (0.47) HTTMAPTPOLBALDH1A1LMNA
SCHEMBL28821084 0.79 CREBBP (0.47) CREBBPKMT2AHTTMEN1MAPT
SCHEMBL22479631 0.79 CREBBP (0.52) CREBBPKMT2AHTTMEN1MAPT
SCHEMBL2896747 0.79 CREBBP (0.52) CREBBPKMT2AHTTMEN1MAPT
SCHEMBL13701759 0.77 EPHX2 (0.46) HTTMAPTPOLBKDM4EALDH1A1
SCHEMBL17865779 0.77 LMNA (0.58) HTTMAPTPOLBLMNASMN1; SMN2
SCHEMBL13875954 0.77 CREBBP (0.43) CREBBPKMT2AHTTMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION C4 Theraprutics, Inc. (US) 2019-03-14 US disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors FLECK ROMAN WOLFGANG 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227588-A1 Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors EPHX1, EPHX2, EPX CREBBP 3027/4885KMT2A 3792/4885HTT 3678/4885
US-20190076539-A1 AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION GCGR, STUB1, GID4 CREBBP 3482/4885KMT2A 2669/4885HTT 261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.